Please login to the form below

Not currently logged in
Email:
Password:

anxiety

This page shows the latest anxiety news and features for those working in and with pharma, biotech and healthcare.

Otsuka’s Alzheimer’s agitation drug hits the mark

Otsuka’s Alzheimer’s agitation drug hits the mark

antipsychotic drugs – which have been linked to a higher risk of death in dementia – as well as antidepressants and anxiety medications.

Latest news

More from news
Approximately 1 fully matching, plus 143 partially matching documents found.

Latest Intelligence

  • Changing healthcare communications Changing healthcare communications

    Replacing anxiety with confidence, mediocrity with purpose. By David Hunt and Lou Shipley. ... But only if we replace anxiety with confidence, mediocrity with purpose, and attract the brightest, smartest and most creative minds to join our cause.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    There were also significant improvements for AbbVie’s drug over Humira on quality of life measures and over Stelara on anxiety and depression, and risankizumab did better than both comparator drugs

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Galbraith is concerned about the rise in reported anxiety and mental health problems in young people, with young women most vulnerable.

  • The Patient Safety Challenge The Patient Safety Challenge

    There were anxieties about how reporting could affect their reputations and career prospects.

  • Finding the patient voice Finding the patient voice

    This data provided the big picture about what motivates people to join clinical trials, their anxieties and their experiences. ... we should communicate with them, depending on their needs and anxieties.

More from intelligence
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest appointments

  • Dr Niall Murphy and Pierre Schwich join Pharnext Dr Niall Murphy and Pierre Schwich join Pharnext

    Prior to this, Dr Murphy served as a unit leader for a team of scientists collaborating on research in the areas of addition biology, Alzheimer's disease, anxiety, depression and neurotoxicity

  • Turing names Eliseo Salinas as head of R&D Turing names Eliseo Salinas as head of R&D

    Salinas has played a leading role in numerous programmes for a range of diseases and disorders, with specific focus on central nervous systems (CNS) condition such as depression and anxiety, schizophrenia,

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 20 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics